公开(公告)号：US10442808B2

公开(公告)日：2019-10-15

申请号：US15729979

申请日：2017-10-11

Applicant: NOVARTIS AG

Inventor： Carole Pissot Soldermann ,  Jean Quancard ,  Achim Schlapbach ,  Oliver Simic ,  Marina Tintelnot-Blomley ,  Thomas Zoller

IPC: A61K31/519 ,  A61K31/5377 ,  C07D487/04

Abstract: The present invention describes new pyrazolo-pyrimidine derivatives according to Formula (I) which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.

公开(公告)号：US20180030061A1

公开(公告)日：2018-02-01

申请号：US15729979

申请日：2017-10-11

Applicant: NOVARTIS AG

Inventor： Carole Pissot Soldermann ,  Jean Quancard ,  Achim Schlapbach ,  Oliver Simic ,  Marina Tintelnot-Blomley ,  Thomas Zoller

IPC: C07D487/04 ,  A61K31/5377 ,  A61K31/519

Abstract: The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.

公开(公告)号：US20130149281A1

公开(公告)日：2013-06-13

申请号：US13764509

申请日：2013-02-11

Applicant: NOVARTIS AG

Inventor： Trixi Brandl ,  Jiping Fu ,  Francois Lenoir ,  David Thomas Parker ,  Michael Patane ,  Branko Radetich ,  Prakash Raman ,  Pascal Rigollier ,  Mohindra Seepersaud ,  Oliver Simic ,  Aregahegn Yifru ,  Rui Zhang

IPC: A61K38/07 ,  A61K45/06 ,  A61K38/06

CPC classification number: A61K38/07 ,  A61K38/00 ,  A61K38/06 ,  A61K45/06 ,  C07D209/96 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/10 ,  C07D491/20 ,  C07D495/10 ,  C07D498/04 ,  C07D498/10 ,  C07K5/06034 ,  C07K5/06078 ,  C07K5/06165 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/101 ,  C07K5/1016

Abstract: The present application describes a method of treating an HCV-associated disorder by administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula I in combination with an additional HCV-modulating compound.

Abstract translation: 本申请描述了通过向有需要的受试者施用药学有效量的式I化合物与另外的HCV调节化合物组合来治疗HCV相关疾病的方法。